Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements.

@article{Hooker2008PopulationPM,
  title={Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements.},
  author={Andrew C. Hooker and Albert J ten Tije and Michael Anthony Carducci and Juliane Weber and Elizabeth L Garrett-Mayer and Hans A.J. Gelderblom and William Patrick McGuire and Jaap Verweij and Mats O. Karlsson and Sharyn D. Baker},
  journal={Clinical pharmacology and therapeutics},
  year={2008},
  volume={84 1},
  pages={111-8}
}
The relationship between cytochrome P4503A4 (CYP3A4) activity and docetaxel clearance in patients with varying degrees of liver function (LF) was evaluated. Docetaxel 40, 50, or 75 mg/m(2) was administered to 85 patients with advanced cancer; 23 of 77 evaluable patients had abnormalities in LF tests. Baseline CYP3A activity was assessed using the erythromycin breath test (ERMBT). Pharmacokinetic studies and toxicity assessments were performed during cycle 1 of therapy and population modeling… CONTINUE READING